Cargando…

Normative Modeling of Brain Morphometry in Clinical High Risk for Psychosis

IMPORTANCE: The lack of robust neuroanatomical markers of psychosis risk has been traditionally attributed to heterogeneity. A complementary hypothesis is that variation in neuroanatomical measures in individuals at psychosis risk may be nested within the range observed in healthy individuals. OBJEC...

Descripción completa

Detalles Bibliográficos
Autores principales: Haas, Shalaila S., Ge, Ruiyang, Agartz, Ingrid, Amminger, G. Paul, Andreassen, Ole A., Bachman, Peter, Baeza, Inmaculada, Choi, Sunah, Colibazzi, Tiziano, Cropley, Vanessa L., de la Fuente-Sandoval, Camilo, Ebdrup, Bjørn H., Fortea, Adriana, Fusar-Poli, Paolo, Glenthøj, Birte Yding, Glenthøj, Louise Birkedal, Haut, Kristen M., Hayes, Rebecca A., Heekeren, Karsten, Hooker, Christine I., Hwang, Wu Jeong, Jahanshad, Neda, Kaess, Michael, Kasai, Kiyoto, Katagiri, Naoyuki, Kim, Minah, Kindler, Jochen, Koike, Shinsuke, Kristensen, Tina D., Kwon, Jun Soo, Lawrie, Stephen M., Lebedeva, Irina, Lee, Jimmy, Lemmers-Jansen, Imke L. J., Lin, Ashleigh, Ma, Xiaoqian, Mathalon, Daniel H., McGuire, Philip, Michel, Chantal, Mizrahi, Romina, Mizuno, Masafumi, Møller, Paul, Mora-Durán, Ricardo, Nelson, Barnaby, Nemoto, Takahiro, Nordentoft, Merete, Nordholm, Dorte, Omelchenko, Maria A., Pantelis, Christos, Pariente, Jose C., Raghava, Jayachandra M., Reyes-Madrigal, Francisco, Røssberg, Jan I., Rössler, Wulf, Salisbury, Dean F., Sasabayashi, Daiki, Schall, Ulrich, Smigielski, Lukasz, Sugranyes, Gisela, Suzuki, Michio, Takahashi, Tsutomu, Tamnes, Christian K., Theodoridou, Anastasia, Thomopoulos, Sophia I., Thompson, Paul M., Tomyshev, Alexander S., Uhlhaas, Peter J., Værnes, Tor G., van Amelsvoort, Therese A. M. J., van Erp, Theo G. M., Waltz, James A., Wenneberg, Christina, Westlye, Lars T., Wood, Stephen J., Zhou, Juan H., Hernaus, Dennis, Jalbrzikowski, Maria, Kahn, René S., Corcoran, Cheryl M., Frangou, Sophia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10568447/
https://www.ncbi.nlm.nih.gov/pubmed/37819650
http://dx.doi.org/10.1001/jamapsychiatry.2023.3850
_version_ 1785119362268528640
author Haas, Shalaila S.
Ge, Ruiyang
Agartz, Ingrid
Amminger, G. Paul
Andreassen, Ole A.
Bachman, Peter
Baeza, Inmaculada
Choi, Sunah
Colibazzi, Tiziano
Cropley, Vanessa L.
de la Fuente-Sandoval, Camilo
Ebdrup, Bjørn H.
Fortea, Adriana
Fusar-Poli, Paolo
Glenthøj, Birte Yding
Glenthøj, Louise Birkedal
Haut, Kristen M.
Hayes, Rebecca A.
Heekeren, Karsten
Hooker, Christine I.
Hwang, Wu Jeong
Jahanshad, Neda
Kaess, Michael
Kasai, Kiyoto
Katagiri, Naoyuki
Kim, Minah
Kindler, Jochen
Koike, Shinsuke
Kristensen, Tina D.
Kwon, Jun Soo
Lawrie, Stephen M.
Lebedeva, Irina
Lee, Jimmy
Lemmers-Jansen, Imke L. J.
Lin, Ashleigh
Ma, Xiaoqian
Mathalon, Daniel H.
McGuire, Philip
Michel, Chantal
Mizrahi, Romina
Mizuno, Masafumi
Møller, Paul
Mora-Durán, Ricardo
Nelson, Barnaby
Nemoto, Takahiro
Nordentoft, Merete
Nordholm, Dorte
Omelchenko, Maria A.
Pantelis, Christos
Pariente, Jose C.
Raghava, Jayachandra M.
Reyes-Madrigal, Francisco
Røssberg, Jan I.
Rössler, Wulf
Salisbury, Dean F.
Sasabayashi, Daiki
Schall, Ulrich
Smigielski, Lukasz
Sugranyes, Gisela
Suzuki, Michio
Takahashi, Tsutomu
Tamnes, Christian K.
Theodoridou, Anastasia
Thomopoulos, Sophia I.
Thompson, Paul M.
Tomyshev, Alexander S.
Uhlhaas, Peter J.
Værnes, Tor G.
van Amelsvoort, Therese A. M. J.
van Erp, Theo G. M.
Waltz, James A.
Wenneberg, Christina
Westlye, Lars T.
Wood, Stephen J.
Zhou, Juan H.
Hernaus, Dennis
Jalbrzikowski, Maria
Kahn, René S.
Corcoran, Cheryl M.
Frangou, Sophia
author_facet Haas, Shalaila S.
Ge, Ruiyang
Agartz, Ingrid
Amminger, G. Paul
Andreassen, Ole A.
Bachman, Peter
Baeza, Inmaculada
Choi, Sunah
Colibazzi, Tiziano
Cropley, Vanessa L.
de la Fuente-Sandoval, Camilo
Ebdrup, Bjørn H.
Fortea, Adriana
Fusar-Poli, Paolo
Glenthøj, Birte Yding
Glenthøj, Louise Birkedal
Haut, Kristen M.
Hayes, Rebecca A.
Heekeren, Karsten
Hooker, Christine I.
Hwang, Wu Jeong
Jahanshad, Neda
Kaess, Michael
Kasai, Kiyoto
Katagiri, Naoyuki
Kim, Minah
Kindler, Jochen
Koike, Shinsuke
Kristensen, Tina D.
Kwon, Jun Soo
Lawrie, Stephen M.
Lebedeva, Irina
Lee, Jimmy
Lemmers-Jansen, Imke L. J.
Lin, Ashleigh
Ma, Xiaoqian
Mathalon, Daniel H.
McGuire, Philip
Michel, Chantal
Mizrahi, Romina
Mizuno, Masafumi
Møller, Paul
Mora-Durán, Ricardo
Nelson, Barnaby
Nemoto, Takahiro
Nordentoft, Merete
Nordholm, Dorte
Omelchenko, Maria A.
Pantelis, Christos
Pariente, Jose C.
Raghava, Jayachandra M.
Reyes-Madrigal, Francisco
Røssberg, Jan I.
Rössler, Wulf
Salisbury, Dean F.
Sasabayashi, Daiki
Schall, Ulrich
Smigielski, Lukasz
Sugranyes, Gisela
Suzuki, Michio
Takahashi, Tsutomu
Tamnes, Christian K.
Theodoridou, Anastasia
Thomopoulos, Sophia I.
Thompson, Paul M.
Tomyshev, Alexander S.
Uhlhaas, Peter J.
Værnes, Tor G.
van Amelsvoort, Therese A. M. J.
van Erp, Theo G. M.
Waltz, James A.
Wenneberg, Christina
Westlye, Lars T.
Wood, Stephen J.
Zhou, Juan H.
Hernaus, Dennis
Jalbrzikowski, Maria
Kahn, René S.
Corcoran, Cheryl M.
Frangou, Sophia
collection PubMed
description IMPORTANCE: The lack of robust neuroanatomical markers of psychosis risk has been traditionally attributed to heterogeneity. A complementary hypothesis is that variation in neuroanatomical measures in individuals at psychosis risk may be nested within the range observed in healthy individuals. OBJECTIVE: To quantify deviations from the normative range of neuroanatomical variation in individuals at clinical high risk for psychosis (CHR-P) and evaluate their overlap with healthy variation and their association with positive symptoms, cognition, and conversion to a psychotic disorder. DESIGN, SETTING, AND PARTICIPANTS: This case-control study used clinical-, IQ-, and neuroimaging software (FreeSurfer)–derived regional measures of cortical thickness (CT), cortical surface area (SA), and subcortical volume (SV) from 1340 individuals with CHR-P and 1237 healthy individuals pooled from 29 international sites participating in the Enhancing Neuroimaging Genetics Through Meta-analysis (ENIGMA) Clinical High Risk for Psychosis Working Group. Healthy individuals and individuals with CHR-P were matched on age and sex within each recruitment site. Data were analyzed between September 1, 2021, and November 30, 2022. MAIN OUTCOMES AND MEASURES: For each regional morphometric measure, deviation scores were computed as z scores indexing the degree of deviation from their normative means from a healthy reference population. Average deviation scores (ADS) were also calculated for regional CT, SA, and SV measures and globally across all measures. Regression analyses quantified the association of deviation scores with clinical severity and cognition, and 2-proportion z tests identified case-control differences in the proportion of individuals with infranormal (z < −1.96) or supranormal (z > 1.96) scores. RESULTS: Among 1340 individuals with CHR-P, 709 (52.91%) were male, and the mean (SD) age was 20.75 (4.74) years. Among 1237 healthy individuals, 684 (55.30%) were male, and the mean (SD) age was 22.32 (4.95) years. Individuals with CHR-P and healthy individuals overlapped in the distributions of the observed values, regional z scores, and all ADS values. For any given region, the proportion of individuals with CHR-P who had infranormal or supranormal values was low (up to 153 individuals [<11.42%]) and similar to that of healthy individuals (<115 individuals [<9.30%]). Individuals with CHR-P who converted to a psychotic disorder had a higher percentage of infranormal values in temporal regions compared with those who did not convert (7.01% vs 1.38%) and healthy individuals (5.10% vs 0.89%). In the CHR-P group, only the ADS SA was associated with positive symptoms (β = −0.08; 95% CI, −0.13 to −0.02; P = .02 for false discovery rate) and IQ (β = 0.09; 95% CI, 0.02-0.15; P = .02 for false discovery rate). CONCLUSIONS AND RELEVANCE: In this case-control study, findings suggest that macroscale neuromorphometric measures may not provide an adequate explanation of psychosis risk.
format Online
Article
Text
id pubmed-10568447
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher American Medical Association
record_format MEDLINE/PubMed
spelling pubmed-105684472023-10-13 Normative Modeling of Brain Morphometry in Clinical High Risk for Psychosis Haas, Shalaila S. Ge, Ruiyang Agartz, Ingrid Amminger, G. Paul Andreassen, Ole A. Bachman, Peter Baeza, Inmaculada Choi, Sunah Colibazzi, Tiziano Cropley, Vanessa L. de la Fuente-Sandoval, Camilo Ebdrup, Bjørn H. Fortea, Adriana Fusar-Poli, Paolo Glenthøj, Birte Yding Glenthøj, Louise Birkedal Haut, Kristen M. Hayes, Rebecca A. Heekeren, Karsten Hooker, Christine I. Hwang, Wu Jeong Jahanshad, Neda Kaess, Michael Kasai, Kiyoto Katagiri, Naoyuki Kim, Minah Kindler, Jochen Koike, Shinsuke Kristensen, Tina D. Kwon, Jun Soo Lawrie, Stephen M. Lebedeva, Irina Lee, Jimmy Lemmers-Jansen, Imke L. J. Lin, Ashleigh Ma, Xiaoqian Mathalon, Daniel H. McGuire, Philip Michel, Chantal Mizrahi, Romina Mizuno, Masafumi Møller, Paul Mora-Durán, Ricardo Nelson, Barnaby Nemoto, Takahiro Nordentoft, Merete Nordholm, Dorte Omelchenko, Maria A. Pantelis, Christos Pariente, Jose C. Raghava, Jayachandra M. Reyes-Madrigal, Francisco Røssberg, Jan I. Rössler, Wulf Salisbury, Dean F. Sasabayashi, Daiki Schall, Ulrich Smigielski, Lukasz Sugranyes, Gisela Suzuki, Michio Takahashi, Tsutomu Tamnes, Christian K. Theodoridou, Anastasia Thomopoulos, Sophia I. Thompson, Paul M. Tomyshev, Alexander S. Uhlhaas, Peter J. Værnes, Tor G. van Amelsvoort, Therese A. M. J. van Erp, Theo G. M. Waltz, James A. Wenneberg, Christina Westlye, Lars T. Wood, Stephen J. Zhou, Juan H. Hernaus, Dennis Jalbrzikowski, Maria Kahn, René S. Corcoran, Cheryl M. Frangou, Sophia JAMA Psychiatry Original Investigation IMPORTANCE: The lack of robust neuroanatomical markers of psychosis risk has been traditionally attributed to heterogeneity. A complementary hypothesis is that variation in neuroanatomical measures in individuals at psychosis risk may be nested within the range observed in healthy individuals. OBJECTIVE: To quantify deviations from the normative range of neuroanatomical variation in individuals at clinical high risk for psychosis (CHR-P) and evaluate their overlap with healthy variation and their association with positive symptoms, cognition, and conversion to a psychotic disorder. DESIGN, SETTING, AND PARTICIPANTS: This case-control study used clinical-, IQ-, and neuroimaging software (FreeSurfer)–derived regional measures of cortical thickness (CT), cortical surface area (SA), and subcortical volume (SV) from 1340 individuals with CHR-P and 1237 healthy individuals pooled from 29 international sites participating in the Enhancing Neuroimaging Genetics Through Meta-analysis (ENIGMA) Clinical High Risk for Psychosis Working Group. Healthy individuals and individuals with CHR-P were matched on age and sex within each recruitment site. Data were analyzed between September 1, 2021, and November 30, 2022. MAIN OUTCOMES AND MEASURES: For each regional morphometric measure, deviation scores were computed as z scores indexing the degree of deviation from their normative means from a healthy reference population. Average deviation scores (ADS) were also calculated for regional CT, SA, and SV measures and globally across all measures. Regression analyses quantified the association of deviation scores with clinical severity and cognition, and 2-proportion z tests identified case-control differences in the proportion of individuals with infranormal (z < −1.96) or supranormal (z > 1.96) scores. RESULTS: Among 1340 individuals with CHR-P, 709 (52.91%) were male, and the mean (SD) age was 20.75 (4.74) years. Among 1237 healthy individuals, 684 (55.30%) were male, and the mean (SD) age was 22.32 (4.95) years. Individuals with CHR-P and healthy individuals overlapped in the distributions of the observed values, regional z scores, and all ADS values. For any given region, the proportion of individuals with CHR-P who had infranormal or supranormal values was low (up to 153 individuals [<11.42%]) and similar to that of healthy individuals (<115 individuals [<9.30%]). Individuals with CHR-P who converted to a psychotic disorder had a higher percentage of infranormal values in temporal regions compared with those who did not convert (7.01% vs 1.38%) and healthy individuals (5.10% vs 0.89%). In the CHR-P group, only the ADS SA was associated with positive symptoms (β = −0.08; 95% CI, −0.13 to −0.02; P = .02 for false discovery rate) and IQ (β = 0.09; 95% CI, 0.02-0.15; P = .02 for false discovery rate). CONCLUSIONS AND RELEVANCE: In this case-control study, findings suggest that macroscale neuromorphometric measures may not provide an adequate explanation of psychosis risk. American Medical Association 2023-10-11 /pmc/articles/PMC10568447/ /pubmed/37819650 http://dx.doi.org/10.1001/jamapsychiatry.2023.3850 Text en Copyright 2023 ENIGMA Clinical High Risk for Psychosis Working Group. JAMA Psychiatry. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the CC-BY License.
spellingShingle Original Investigation
Haas, Shalaila S.
Ge, Ruiyang
Agartz, Ingrid
Amminger, G. Paul
Andreassen, Ole A.
Bachman, Peter
Baeza, Inmaculada
Choi, Sunah
Colibazzi, Tiziano
Cropley, Vanessa L.
de la Fuente-Sandoval, Camilo
Ebdrup, Bjørn H.
Fortea, Adriana
Fusar-Poli, Paolo
Glenthøj, Birte Yding
Glenthøj, Louise Birkedal
Haut, Kristen M.
Hayes, Rebecca A.
Heekeren, Karsten
Hooker, Christine I.
Hwang, Wu Jeong
Jahanshad, Neda
Kaess, Michael
Kasai, Kiyoto
Katagiri, Naoyuki
Kim, Minah
Kindler, Jochen
Koike, Shinsuke
Kristensen, Tina D.
Kwon, Jun Soo
Lawrie, Stephen M.
Lebedeva, Irina
Lee, Jimmy
Lemmers-Jansen, Imke L. J.
Lin, Ashleigh
Ma, Xiaoqian
Mathalon, Daniel H.
McGuire, Philip
Michel, Chantal
Mizrahi, Romina
Mizuno, Masafumi
Møller, Paul
Mora-Durán, Ricardo
Nelson, Barnaby
Nemoto, Takahiro
Nordentoft, Merete
Nordholm, Dorte
Omelchenko, Maria A.
Pantelis, Christos
Pariente, Jose C.
Raghava, Jayachandra M.
Reyes-Madrigal, Francisco
Røssberg, Jan I.
Rössler, Wulf
Salisbury, Dean F.
Sasabayashi, Daiki
Schall, Ulrich
Smigielski, Lukasz
Sugranyes, Gisela
Suzuki, Michio
Takahashi, Tsutomu
Tamnes, Christian K.
Theodoridou, Anastasia
Thomopoulos, Sophia I.
Thompson, Paul M.
Tomyshev, Alexander S.
Uhlhaas, Peter J.
Værnes, Tor G.
van Amelsvoort, Therese A. M. J.
van Erp, Theo G. M.
Waltz, James A.
Wenneberg, Christina
Westlye, Lars T.
Wood, Stephen J.
Zhou, Juan H.
Hernaus, Dennis
Jalbrzikowski, Maria
Kahn, René S.
Corcoran, Cheryl M.
Frangou, Sophia
Normative Modeling of Brain Morphometry in Clinical High Risk for Psychosis
title Normative Modeling of Brain Morphometry in Clinical High Risk for Psychosis
title_full Normative Modeling of Brain Morphometry in Clinical High Risk for Psychosis
title_fullStr Normative Modeling of Brain Morphometry in Clinical High Risk for Psychosis
title_full_unstemmed Normative Modeling of Brain Morphometry in Clinical High Risk for Psychosis
title_short Normative Modeling of Brain Morphometry in Clinical High Risk for Psychosis
title_sort normative modeling of brain morphometry in clinical high risk for psychosis
topic Original Investigation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10568447/
https://www.ncbi.nlm.nih.gov/pubmed/37819650
http://dx.doi.org/10.1001/jamapsychiatry.2023.3850
work_keys_str_mv AT normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis
AT haasshalailas normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis
AT geruiyang normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis
AT agartzingrid normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis
AT ammingergpaul normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis
AT andreassenolea normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis
AT bachmanpeter normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis
AT baezainmaculada normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis
AT choisunah normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis
AT colibazzitiziano normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis
AT cropleyvanessal normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis
AT delafuentesandovalcamilo normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis
AT ebdrupbjørnh normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis
AT forteaadriana normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis
AT fusarpolipaolo normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis
AT glenthøjbirteyding normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis
AT glenthøjlouisebirkedal normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis
AT hautkristenm normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis
AT hayesrebeccaa normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis
AT heekerenkarsten normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis
AT hookerchristinei normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis
AT hwangwujeong normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis
AT jahanshadneda normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis
AT kaessmichael normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis
AT kasaikiyoto normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis
AT katagirinaoyuki normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis
AT kimminah normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis
AT kindlerjochen normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis
AT koikeshinsuke normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis
AT kristensentinad normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis
AT kwonjunsoo normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis
AT lawriestephenm normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis
AT lebedevairina normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis
AT leejimmy normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis
AT lemmersjansenimkelj normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis
AT linashleigh normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis
AT maxiaoqian normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis
AT mathalondanielh normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis
AT mcguirephilip normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis
AT michelchantal normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis
AT mizrahiromina normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis
AT mizunomasafumi normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis
AT møllerpaul normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis
AT moraduranricardo normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis
AT nelsonbarnaby normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis
AT nemototakahiro normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis
AT nordentoftmerete normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis
AT nordholmdorte normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis
AT omelchenkomariaa normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis
AT pantelischristos normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis
AT parientejosec normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis
AT raghavajayachandram normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis
AT reyesmadrigalfrancisco normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis
AT røssbergjani normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis
AT rosslerwulf normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis
AT salisburydeanf normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis
AT sasabayashidaiki normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis
AT schallulrich normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis
AT smigielskilukasz normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis
AT sugranyesgisela normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis
AT suzukimichio normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis
AT takahashitsutomu normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis
AT tamneschristiank normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis
AT theodoridouanastasia normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis
AT thomopoulossophiai normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis
AT thompsonpaulm normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis
AT tomyshevalexanders normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis
AT uhlhaaspeterj normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis
AT værnestorg normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis
AT vanamelsvoortthereseamj normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis
AT vanerptheogm normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis
AT waltzjamesa normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis
AT wennebergchristina normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis
AT westlyelarst normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis
AT woodstephenj normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis
AT zhoujuanh normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis
AT hernausdennis normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis
AT jalbrzikowskimaria normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis
AT kahnrenes normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis
AT corcorancherylm normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis
AT frangousophia normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis